Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

  • March 2, 2026

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic dysfunction-associated steatohepatitis (MASH) candidate.

Leave A Comment

Fields (*) Mark are Required